Cardiovascular Safety During Biologic Therapy for Psoriasis: A Class‐Wide Systematic Review and Meta‐Analysis
Dermatologic Therapy · 2026-01 · 2026 (1)
DOI: 10.1155/dth/8514168 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Dermatologic Therapy, online erschienen am 31.07.2026. Verfasst von Mária Veronika Kolonics und 14 weiteren Autor:innen. Die Arbeit nennt 182 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research, Development and Innovation Office, Semmelweis Egyetem.
Abstract (Originalsprache)
Background
Psoriasis is an immune‐mediated inflammatory disease (IMID) with elevated cardiovascular (CV) risk. Biological therapies for psoriasis are highly effective and have a favourable safety profile; nevertheless, studies have suggested that some therapeutical agents may increase the risk of major adverse cardiovascular events (MACEs).
Objectives
To clarify CV safety across all four biologic classes used in psoriasis by quantifying MACE and related outcomes by conducting a systematic review and meta‐analysis.
Methods
A systematic search up to November 2024 was conducted for randomised and nonrandomised studies of tumour necrosis factor inhibitors, interleukin (IL)‐12/23, IL‐17 and IL‐23 inhibitors in psoriasis. Outcomes were MACE, myocardial infarction (MI), ischaemic stroke, CV mortality (CVM) and heart failure (HF). Pooled proportions with 95% confidence intervals (CIs) were calculated by class.
Results
127 studies were included, comprising 67,344 patients. Across all biologic classes, pooled proportions for MACE (0.0015–0.0041), MI (0.0017–0.0046), stroke (0.0003–0.0023), CVM (0.0005–0.0011) and HF (0.0016–0.0065) were low.
Conclusions
Biological therapies for psoriasis showed low CV event rates across all four biologic classes, with no indication of increased CV risk. These findings support their CV safety, although further long‐term studies in high‐risk populations are warranted.
Förderung
- National Research, Development and Innovation Office
- Semmelweis Egyetem
Zitieren
APA
Kolonics, M. V., Martyin, K., Galajda, N. Á., Meznerics, F. A., Abed, A., Fazekas, K. K., Krebs, M., Ungvári, Á., Czibulya, A., Kulyassa, P., Kemény, L. V., Kiss, N., Hegyi, P., Bánvölgyi, A., & Holló, P. (2026). Cardiovascular Safety During Biologic Therapy for Psoriasis: A Class‐Wide Systematic Review and Meta‐Analysis. Dermatologic Therapy, 2026(1). https://doi.org/10.1155/dth/8514168
Vancouver
Kolonics MV, Martyin K, Galajda NÁ, Meznerics FA, Abed A, Fazekas KK, et al. Cardiovascular Safety During Biologic Therapy for Psoriasis: A Class‐Wide Systematic Review and Meta‐Analysis. Dermatologic Therapy. 2026;2026(1). doi:10.1155/dth/8514168
BibTeX
@article{Kolonics2026,
author = {Kolonics, Mária Veronika and Martyin, Katalin and Galajda, Noémi Ágnes and Meznerics, Fanni Adél and Abed, Adib and Fazekas, Karen Krisztina and Krebs, Máté and Ungvári, Ákos and Czibulya, Anna and Kulyassa, Péter and Kemény, Lajos Vince and Kiss, Norbert and Hegyi, Péter and Bánvölgyi, András and Holló, Péter},
title = {Cardiovascular Safety During Biologic Therapy for Psoriasis: A Class‐Wide Systematic Review and Meta‐Analysis},
journal = {Dermatologic Therapy},
year = {2026},
volume = {2026},
number = {1},
doi = {10.1155/dth/8514168}
}
EUVIMED